MedPath
Found 5 clinical trials|View Analysis
Sort by:

Ziftomenib Maintenance Post Allo-HCT

Phase 1
Not yet recruiting
Conditions
Acute Myeloid Leukemia
Acute Myeloid Leukemia in Remission
NPM1 Mutation
KMT2A Rearrangement
Interventions
First Posted Date
2024-06-03
Last Posted Date
2024-06-03
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
22
Registration Number
NCT06440135
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Phase 1
Recruiting
Conditions
Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia With KMT2A Rearrangement
Acute Myeloid Leukemia With FLT3/ITD Mutation
Acute Myeloid Leukemia With NPM1 Mutation
Recurrent Acute Myeloid Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Gilteritinib
Drug: Revumenib
First Posted Date
2024-01-24
Last Posted Date
2024-05-22
Lead Sponsor
Uma Borate
Target Recruit Count
30
Registration Number
NCT06222580
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Phase 1
Recruiting
Conditions
Acute Myeloid Leukemia With KMT2A Rearrangement
Acute Myeloid Leukemia With NPM1 Mutation
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Multigated Acquisition Scan
Drug: Revumenib
Procedure: Transthoracic Echocardiography
First Posted Date
2023-06-02
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT05886049
Locations
🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 10 locations

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1
Recruiting
Conditions
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Lineage Acute Leukemia
Acute Leukemia of Ambiguous Lineage
Interventions
First Posted Date
2019-08-22
Last Posted Date
2024-11-21
Lead Sponsor
Syndax Pharmaceuticals
Target Recruit Count
413
Registration Number
NCT04065399
Locations
🇫🇷

Hospital Saint-Louis - APHP, Paris, France

🇫🇷

Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France

🇩🇪

University Hospital Of Ulm, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany

and more 54 locations

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Phase 2
Active, not recruiting
Conditions
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Acute Leukemia of Ambiguous Lineage
Interventions
First Posted Date
2016-07-11
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
78
Registration Number
NCT02828358
Locations
🇺🇸

Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States

🇺🇸

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States

🇺🇸

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States

and more 169 locations
© Copyright 2025. All Rights Reserved by MedPath